Enhancing treatment for glioblastoma by targeting tumor inflammation
Official title: Improving Glioma Immunotherapy Efficacy by Regulating Tumor Inflammation
Funded at Beckman Research Institute/city of Hope · NIH-10912015 · Data updated 2026-11-12
This study is looking at a new way to make immunotherapy work better for people with glioblastoma, a tough type of brain cancer, by blocking a specific receptor that helps the tumor grow, and patients may have the chance to participate in trials testing this promising approach.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Beckman Research Institute/city of Hope NIH-funded |
| Lab location | 1 site (Duarte, United States) |
| Project start | September 1, 2023 |
| Project end | August 31, 2028 |
| Funding year | 2024 |
| Award (this year) | $570,541 |
| NIH project number | 5R01NS134116-02 |
| Project ID | NIH-10912015 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with glioblastoma who have not responded well to standard therapies.
✕Less likely to help
Patients with other types of brain tumors or those who are not diagnosed with glioblastoma may not benefit from this research.
What this research studies
This research investigates how to improve the effectiveness of immunotherapy for glioblastoma, a type of brain cancer known for its aggressive nature and poor survival rates. The approach focuses on inhibiting a specific receptor, RAGE, which is involved in promoting tumor growth and resistance to treatment. By targeting RAGE, the researchers aim to create a more favorable environment for immunotherapy to work effectively against glioblastoma. Patients may be involved in trials that explore this innovative treatment strategy.
Why it matters
Potential benefit: If successful, this research could significantly improve survival rates and treatment outcomes for patients with glioblastoma.
How similar studies have gone: Previous research has shown promising results in targeting similar pathways for enhancing immunotherapy efficacy in cancer treatment.
Where this research is happening
-
Beckman Research Institute/city of Hope
Duarte, United States Active
Researchers
- Principal investigator: Badie, Behnam — Beckman Research Institute/city of Hope
- Study coordinator: Badie, Behnam
Related research
Other NIH-funded projects on the same topics.
-
Innate immune memory to help glioblastoma therapy
A Duke team is testing a weakened poliovirus treatment that could boost the body's immune attack on glioblastoma in patients who have the tumor.
-
Improving glioblastoma treatment by targeting tumor inflammation
This project looks at using a new approach to help brain cancer patients with glioblastoma respond better to immunotherapy by reducing harmful inflammation in the tumor.
-
Augmenting immunotherapy effects in glioma patients
A trial aims to see if adding DFMO to pembrolizumab can boost immune response and help people with grade 4 astrocytomas.
-
Boosting immune therapy for glioblastoma by controlling tumor inflammation
This project will try blocking the RAGE protein to help immune treatments work better for people with glioblastoma.
-
Investigating how glioma tumors respond to immunotherapy
This study is looking at why some people with glioblastoma, a type of brain cancer, benefit from immunotherapy while others don’t, by examining tumor samples and patient information to find clues that could help improve treatment for everyone.
-
Boosting immune response to fight cancer
This study is exploring a new way to help your immune system better fight cancer by tweaking certain cells in your body, and it aims to improve treatment for people with advanced cancer.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.